International Journal of Antimicrobial Agents

Article	Citations
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	3251
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality	1270
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	717
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence	705
Coronavirus disease 2019 (COVID-19): current status and future perspectives	697
The epidemiology, diagnosis and treatment of COVID-19	603
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection	422
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies	399
Increased antimicrobial resistance during the COVID-19 pandemic	248
Extra-respiratory manifestations of COVID-19	220
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking	201
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies	185
SARS-CoV-2 was already spreading in France in late December 2019	185
Procalcitonin levels in COVID-19 patients	184
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein	178
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update	153
Tocilizumab for severe COVID-19: a systematic review and meta-analysis	130
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)	130
Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment	117
Different mutations in SARS-CoV-2 associate with severe and mild outcome	115
Ribavirin therapy for severe COVID-19: a retrospective cohort study	113
Lactoferrin as potential preventative and adjunct treatment for COVID-19	111
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19	97
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants	96
Drug repositioning is an alternative for the treatment of coronavirus COVID-19	88

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients	87
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line	85
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19	82
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies	80
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment	80
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic	79
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study	79
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology	79
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal	78
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19	78
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal	77
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949	73
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors	68
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial	68
Long-acting drugs and formulations for the treatment and prevention of HIV infection	66
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients	61
SARS-CoV-2: fear versus data	57
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial	57
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli	56
Combating devastating COVID-19 by drug repurposing	56
Addressing the challenges in antisepsis: focus on povidone iodine	55
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?	51
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19	51
Methylene blue inhibits replication of SARS-CoV-2 in vitro	51
Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948]	50
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections	49
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance	49
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine	49
Targeting antimicrobial drug resistance with marine natural products	47
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial	46
Cardiac effects and toxicity of chloroquine: a short update	43
Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications	42
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin	41
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections	40
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports	39
In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumi	39
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infecti	38
Is teicoplanin a complementary treatment option for COVID-19? The question remains	38
Octenidine: Novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level	37
Emergence of a novel conjugative hybrid virulence multidrug-resistant plasmid in extensively drug-resistant Klebsiella pneumoniae ST15	37
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin	37
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?	36
Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital	36
High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade	36
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection	35
Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes	35
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals	35
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial	34
Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration–time curve against a trough 15–20 μg/mL concentration	33
Identification of mobile colistin resistance genes (mcr-1.1, mcr-5 and mcr-8.1) in Enterobacteriaceae and Alcaligenes faecalis of human and animal origin, Nigeria	32

Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis	32
Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection	32
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis	32
A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa	31
Bacteriophage–antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model	30
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae	29
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections	29
Effect of antibiotics on the human microbiome: a systematic review	29
Epidemiology and prevalence of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa	29
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited	28
Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination	28
Chloroquine as a prophylactic agent against COVID-19?	27
Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris	27
Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review	27
Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia	27
Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review	27
Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns	26
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?	26
Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19)	26
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid	26
Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?	26
Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort	26
Extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a ‘One Health’ study	25
Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care	25
Tocilizumab in COVID-19: Beware the risk of intestinal perforation	24
Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland	24
An insight into the implementation of the global action plan on antimicrobial resistance in the WHO African region: A roadmap for action	24
Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance	23
Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies	23
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial	23
Corticosteroid therapy for patients with COVID-19 pneumonia: a before–after study	23
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany	23
A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial	23
Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2	23
Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy	23
Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: high prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea	22
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature	22
Evaluation of peptoid mimics of short, lipophilic peptide antimicrobials	22
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance	22
Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas	22
Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus	22
Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections	22
Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics	22
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa	21
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values	21
RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae	21
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019	21
Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015–2019	21
Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study	21
Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine	21
The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)	21
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020	21
Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment	20
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients	20
Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model	20
Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper	20
Fosfomycin for bacterial prostatitis: a review	20
Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012–2016	19
Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and	19
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept	19
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs	19
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes	18
Management of Comorbidities in Treated HIV Infection: A Long Way to Go	18
Therapeutic modalities and novel approaches in regenerative medicine for COVID-19	18
In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015–2017	18
In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany	18
Spinal implant-associated infections: a prospective multicentre cohort study	18
Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2	18
Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland	18
Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives	18
SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study	18
How preclinical infection models help define antibiotic doses in the clinic	18
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics	17
Evaluation of area under the concentration–time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury	17
Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome rank	17
Genomic and phenotypic characterisation of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79 and CC25	17
Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond	17
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices	17
The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids	17
What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling	17

Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales	17
Hot topics in diabetic foot infection	17
Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998–2019	16
Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by th	16
Complex emergencies of COVID-19: management and experience in Zhuhai, China	16
Antimicrobial production by strictly anaerobic Clostridium spp.	16
Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection	16
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19	16
Evolutionary landscapes of Pseudomonas aeruginosa towards ribosome-targeting antibiotic resistance depend on selection strength	16
Change in Antimicrobial Use During COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study	16
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-n	16
Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015–2017)	16
Plasma medicine and wound management: Evaluation of the antibacterial efficacy of a medically certified cold atmospheric argon plasma jet	16
Office-based approach to urinary tract infections in 50 000 patients: results from the REWIND study	16
In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens	16
LPD-12: a promising lipopeptide to control COVID-19	16
Widespread high-risk clones of multidrug-resistant extended-spectrum β-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments	16
Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections	16
Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review	16
Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice	15
Current trends in the real-life use of dalbavancin: report of a study panel	15
Discovery of macrozones, new antimicrobial thiosemicarbazone-based azithromycin conjugates: design, synthesis and in vitro biological evaluation	15
Publishing in face of the COVID-19 pandemic	15
A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting	15
Adaptation of a Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses – A reply to Fear versus Data	15
Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations	15
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results	15
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections	15
Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review	15
Outpatient antibiotic use associated with acute upper respiratory infections in China: a nationwide cross-sectional study	15
Vertical transmission and kidney damage in newborns whose mothers had coronavirus disease 2019 during pregnancy	14
Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy	14
Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study	14
Evaluation of early antibiotic use in patients with non‐severe COVID‐19 without bacterial infection	14
Synergistic phage–surfactant combination clears IgE-promoted Staphylococcus aureus aggregation in vitro and enhances the effect in vivo	14
Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance	14
Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016–2020)	14
Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study	14
Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics	14
Recommended Antibiotic Dosage Regimens in Critically Ill Patients with Augmented Renal Clearance: A Systematic Review	14
Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study	14
Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing	14
Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales	14
Antibiotic resistance in Enterobacter hormaechei	14
Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam	14
Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data	13
Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study	13
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study	13
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae	13
Preferences regarding antibiotic treatment and the role of antibiotic resistance: A discrete choice experiment	13
The effect of Ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms	13
Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results f	13
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)	13
Antibody-based strategies in HIV therapy	13
Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility	13
Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients	13
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis	13
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactam	13
Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines	13
Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance	13
Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniae	13
4-Ethoxybenzoic acid inhibits Staphylococcus aureus biofilm formation and potentiates biofilm sensitivity to vancomycin	13
Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice	13
Effect of lipid A aminoarabinosylation on Pseudomonas aeruginosa colistin resistance and fitness	12
Disruption of biofilms and killing of Burkholderia cenocepacia from cystic fibrosis lung using an antioxidant-antibiotic combination therapy	12
Passive immunization and its rebirth in the era of the COVID-19 pandemic	12
Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review	12
Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017–2018), and on clonal distribution of MRSA	12
Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital	12
Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil	12
A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression	12
Dissemination of a ‘rare’ extended-spectrum β-lactamase gene blaSFO-1 mediated by epidemic clones of carbapenemase-producing Enterobacter hormaechei in China	12
Assessment of polymyxin B–doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia	12
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects	12
Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk	12
Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltr	12
Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas ae	12
In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from	12
Acinetobacter baumannii strains isolated from cerebrospinal fluid (CSF) and bloodstream analysed by cgMLST: the dominance of clonal complex CC92 in CSF infections	12
Ampicillin triggers the release of Pal in toxic vesicles from Escherichia coli	12
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based	11
Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time	11
Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections	11
The cathelicidin-derived close-to-nature peptide D-11 sensitises Klebsiella pneumoniae to a range of antibiotics in vitro, ex vivo and in vivo	11
Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models	11
Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal	11
CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy	11
Colistin- and tigecycline-resistant CTX-M-14-producing Salmonella enterica serovar Kentucky ST198 from retail chicken meat, China	11
Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing	11
Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study)	11
Machine learning in predicting antimicrobial resistance: a systematic review and meta-analysis	11
Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii	11
Large-scale survey of parental antibiotic use for paediatric upper respiratory tract infections in China: implications for stewardship programmes and national policy	11
Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea	11
Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration	11